Blueprint Genetics accepted into the Tekes NIY program

Published on December 12, 2013

We are happy to announce that Blueprint Genetics has been accepted into the NIY program of Tekes (The Finnish National Technology Agency). The program has two phases that enables us to withdraw up to one million euros in subvention when challenging objectives are met. The idea of the program is to select Finnish technology companies that have a significant international potential and accelerate the development of the companies with non-dilutive financing.

Since launching our first products in June 2013, we have expanded our international customer hospital base with a steady pace. Based on the excellent feedback from our customers we are encouraged to expand our presence to other new countries. During the autumn we have been present in several international conferences from St. Petersburg to Dallas. The Tekes NIY program provides a perfect supportive platform for our further efforts and we will start the expansion by targeting selected EU countries.

In 2012 there were 31 Finnish companies that got accepted into the NIY program and we are extremely glad to join the batch of 2013. According to the Tekes website, the companies are evaluated using the following criteria: international competitiveness of the company, market potential, resources, ability to execute, capability and willingness to grow fast and the ability to raise external financing.

We also feel that we fit this criteria well and we have a clear direction for our work: setting a new standard for genetic diagnostics in hospitals around the world. The acceptance into the NIY program will give us a clear push towards this goal in the forthcoming year of 2014!

Tommi Lehtonen

Last modified: 12.12.2013

News

Blueprint Genetics strengthens its pharmaceutical expertise with new Chairman Hilde Furberg and by appointing Guido Oelkers as a Senior Advisor

Published on December 5, 2018

Blueprint Genetics has gained worldwide momentum and continued global growth in the field of clinical genetic testing of rare inherited diseases. As one of the fastest growing clinical genetic testing businesses globally, Blueprint Genetics has a customer base spanning more than 40 countries. Today, Blueprint Genetics is proud to announce…

Read more

Subscribe to our newsletter